

Ofev - (100, 150 mg; Capsule, Oral)

Generic Name	Nintedanib	Innovator	Boehringer Ingelheim
Dosage	100, 150 mg; Capsule, Oral	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	More Than 5
Final Approvals	None	Generic Launches	None
Indication	Ofev is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.